X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy candidate VRDN-001, for the treatment of thyroid eye disease (TED).
Lead Product(s): VRDN-001
Therapeutic Area: Immunology Product Name: VRDN-001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Viridian Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 26, 2023
Details:
Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and to ensure redundancy of supply, Ypsomed will provide injector dosing pens from their manufacturing facilities.
Lead Product(s): Insulin Glargine
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Civica Rx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
